Harmony Biosciences/$HRMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ticker
$HRMY
Sector
Primary listing
Employees
293
Headquarters
Website
HRMY Metrics
BasicAdvanced
$2bn
14.21
$2.48
0.94
-
Price and volume
Market cap
$2bn
Beta
0.94
52-week high
$40.87
52-week low
$25.52
Average daily volume
849k
Financial strength
Current ratio
3.583
Quick ratio
3.447
Long term debt to equity
15.746
Total debt to equity
18.082
Interest coverage (TTM)
13.49%
Profitability
EBITDA (TTM)
214.85
Gross margin (TTM)
76.55%
Net profit margin (TTM)
16.20%
Operating margin (TTM)
21.08%
Effective tax rate (TTM)
26.30%
Revenue per employee (TTM)
$3,070,000
Management effectiveness
Return on assets (TTM)
10.18%
Return on equity (TTM)
17.86%
Valuation
Price to earnings (TTM)
14.211
Price to revenue (TTM)
2.258
Price to book
2.24
Price to tangible book (TTM)
2.47
Price to free cash flow (TTM)
7.369
Free cash flow yield (TTM)
13.57%
Free cash flow per share (TTM)
4.782
Growth
Revenue change (TTM)
20.71%
Earnings per share change (TTM)
-5.41%
3-year revenue growth (CAGR)
23.99%
3-year earnings per share growth (CAGR)
-7.13%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
HRMY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.